MaxCyte vs NRC Health
MXCT and NRC side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MXCT and NRC compare
NRC Health is the larger company, worth 5.2 times as much as MaxCyte ($594M against $114M).
NRC Health grew revenue faster over the last twelve months (3.4% versus −0.13% for MaxCyte).
NRC Health pays a dividend yielding 2.4%; MaxCyte does not pay one.
MaxCyte scores higher on the StockData Score (11 against 6 for NRC Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MXCT | NRC |
|---|---|---|
| Size and price | ||
| Market cap | $114M | $594M |
| Share price | $1.10 | $26.86 |
| Change, 1 year | −25.2% | 85.5% |
| Change, 5 years | −91.4% | −36.9% |
| Beta (5Y) | 1.53 | 0.51 |
| Employees | 91 | 357 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/S | 3.3× (better) | 4.1× |
| P/B | 0.8× | – |
| EV/EBITDA | – | 28.4× |
| P/FCF | – | 32.2× |
| FCF yield | −18.9% | 3.1% (better) |
| Fair value | $3.17 | $14.71 |
| Margin of safety | 65.3% (better) | −82.6% |
| Growth | ||
| Revenue growth (TTM) | −0.13% | 3.4% (better) |
| Revenue growth, 5Y average | 4.8% (better) | 0.61% |
| EPS growth, 5Y average | – | 103% |
| Profitability | ||
| Gross margin | 81.0% | – |
| Operating margin | −98.0% | 11.1% (better) |
| Net margin | −81.4% | – |
| FCF margin | −62.4% | 12.8% (better) |
| Return on equity | −16.9% | – |
| Return on invested capital | −42.9% | 10.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 4.07 |
| Interest coverage | – | 2.9× |
| Current ratio | 7.83 (better) | 0.64 |
| Altman Z-score | 0.31 | 3.45 (better) |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 2.4% |
| Years of dividend growth | – | 1 |
| Dividend growth, 5Y average | – | 19.9% |
| Buyback yield | – | 4.3% |
| Shareholder yield | 0.00% | 6.7% (better) |
| Ownership | ||
| Held by institutions | 61.3% | 48.6% |
| Held by insiders | 8.0% | 50.4% |
| Insider net buying, 12 months | −$8.3K | $98.2K (better) |
| Short interest, % of float | 1.7% | 6.3% |
Go deeper
- MXCT stock overview
- MXCT income statement
- MXCT valuation and score
- NRC stock overview
- NRC income statement
- NRC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.